Myopia Profile

SightGlass Vision

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research based on the unique contrast theory. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.

SightGlass Vision sponsored articles.

All we’ve learnt in a year about the SightGlass Vision Diffusion Optics Technology™ spectacle lensExplore new research on SightGlass Vision DOTâ„¢ lenses, their efficacy in myopia control, and clinical insights.Read Full Article The SightGlass Vision DOT™ spectacles lens IMC 2024 showcaseWe summarize the new research presented at the 2024 International Myopia Conference by SightGlass Vision and partners. Read Full Article The SightGlass DOT spectacles lens ARVO 2024 showcaseWe summarise 4 posters SightGlass Vision presented at ARVO 2024 on Diffusion Optics Technology (DOT) spectacle lenses. Read Full Article
All we’ve learnt in a year about the SightGlass Vision Diffusion Optics Technology™ spectacle lensExplore new research on SightGlass Vision DOTâ„¢ lenses, their efficacy in myopia control, and clinical insights.Read Full Article

SightGlass Vision myopia management products

Myopia management products listed by Myopia Profile have been specifically designed for myopia control or myopia management in children, and have some form of regulatory approval or marking for this form of use. They also have randomized controlled trial research data supporting their efficacy, unless otherwise noted. It is up to the individual eye care practitioner to be aware of regulatory requirements for prescribing in their country of practice, and also be aware that not all products are available in all countries.

SightGlass Vision DOT Lens

The SightGlass Vision DOT 0.2 lens can be considered a first-line treatment for myopia in children, with one-year randomized controlled trial data published, showing robust myopia control efficacy. They are underpinned by a different mechanism and theory of myopia control than other designs - based on contrast theory rather than optical defocus theory. The DOT 0.2 lens incorporate incorporate Diffusion Optics Technology (DOT™): thousands of microscopic light scattering elements (microdots), each about one tenth of a millimetre wide. The microdots are not designed to produce peripheral defocus - they are designed to mimic more natural contrast while providing clinically equivalent visual experience to single vision lenses. DOT spectacle lenses manage contrast by softly scattering light before it hits the retina, and before the retina detects artificial contrast and signals the eye to elongate. 

More about SightGlass Vision DOT Lens

SightGlass Vision resources

Diffusion Optics Technology

Learn more about Diffusion Optics Technology at the SightGlass Vision website. 

Visit the SightGlass Vision website